FORESEE PHARMACEUTICALS CO., LTD.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
1. CAMCEVI 42 mg
2. CAMCEVI 21 mg
3. FP-025
4. FP-045
5. Aderamastat (FP-025) Phase 2 Study
2. CAMCEVI 21 mg
3. FP-025
4. FP-045
5. Aderamastat (FP-025) Phase 2 Study
Founded Year
2013
Unified Business No.
54165507
Status
Active
Number of Employees
12
Total Paid-in
Capital
1,575,375,410 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
OTC listing(2018)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competencyincludes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.
